Even though the blockage of IL-31, a Th2 interleukin involved in AD, would induce improvement of inflammation and pruritus, there are still unclear points to be addressed when blocking the IL-31 pathway; IL-31 antagonism in AD treatment needs more elucidation once it is not clear whether its effects include only symptomatic, antipruritic relief [71]. This evidence concerns the gene IL31 and Alzheimer disease.